Goldman Sachs’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-130,339
| Closed | -$228K | – | 6365 |
|
|
2025
Q1 | $228K | Sell |
130,339
-82,040
| -39% | -$108K | ﹤0.01% | 5582 |
|
|
2024
Q4 | $336K | Buy |
212,379
+33,374
| +19% | +$51.3K | ﹤0.01% | 5452 |
|
|
2024
Q3 | $281K | Buy |
179,005
+40,540
| +29% | +$67.1K | ﹤0.01% | 5330 |
|
|
2024
Q2 | $247K | Sell |
138,465
-88,954
| -39% | -$206K | ﹤0.01% | 5181 |
|
|
2024
Q1 | $655K | Buy |
+227,419
| New | +$371K | ﹤0.01% | 4598 |
|
|
2021
Q2 | – | Sell |
-1,805
| Closed | -$28K | – | 6470 |
|
|
2021
Q1 | $28K | Sell |
1,805
-3,829
| -68% | -$56.7K | ﹤0.01% | 5992 |
|
|
2020
Q4 | $76K | Buy |
+5,634
| New | +$41.4K | ﹤0.01% | 5331 |
|
|
2018
Q3 | – | Sell |
-139
| Closed | -$11K | – | 5756 |
|
|
2018
Q2 | $11K | Buy |
+139
| New | +$11.5K | ﹤0.01% | 5536 |
|
|
2017
Q3 | – | Sell |
-3,069
| Closed | -$363K | – | 6821 |
|
|
2017
Q2 | $363K | Buy |
3,069
+2,007
| +189% | +$335K | ﹤0.01% | 5349 |
|
|
2017
Q1 | $210K | Sell |
1,062
-842
| -44% | -$160K | ﹤0.01% | 5706 |
|
|
2016
Q4 | $514K | Sell |
1,904
-1,398
| -42% | -$454K | ﹤0.01% | 5041 |
|
|
2016
Q3 | $1.31M | Sell |
3,302
-3,171
| -49% | -$1.3M | ﹤0.01% | 4169 |
|
|
2016
Q2 | $2.25M | Buy |
6,473
+22
| +0.3% | +$15.8K | ﹤0.01% | 3523 |
|
|
2016
Q1 | $5.36M | Buy |
6,451
+236
| +4% | +$188K | ﹤0.01% | 2671 |
|
|
2015
Q4 | $6.5M | Buy |
6,215
+544
| +10% | +$545K | ﹤0.01% | 2594 |
|
|
2015
Q3 | $4.45M | Sell |
5,671
-1,137
| -17% | -$1.17M | ﹤0.01% | 2983 |
|
|
2015
Q2 | $8.95M | Buy |
6,808
+117
| +2% | +$189K | ﹤0.01% | 2426 |
|
|
2015
Q1 | $13.6M | Buy |
6,691
+2,107
| +46% | +$4.58M | ﹤0.01% | 2049 |
|
|
2014
Q4 | $8.82M | Sell |
4,584
-1,764
| -28% | -$3.14M | ﹤0.01% | 2459 |
|
|
2014
Q3 | $5.2M | Sell |
6,348
-245
| -4% | -$207K | ﹤0.01% | 2971 |
|
|
2014
Q2 | $6.36M | Buy |
6,593
+56
| +0.9% | +$48K | ﹤0.01% | 2764 |
|
|
2014
Q1 | $7.08M | Sell |
6,537
-1,323
| -17% | -$1.47M | ﹤0.01% | 2673 |
|
|
2013
Q4 | $6.97M | Buy |
7,860
+652
| +9% | +$561K | ﹤0.01% | 2713 |
|
|
2013
Q3 | $8.16M | Buy |
7,208
+1,982
| +38% | +$2.34M | ﹤0.01% | 2451 |
|
|
2013
Q2 | $6.15M | Buy |
+5,226
| New | +$4.97M | ﹤0.01% | 2534 |
|
Other funds holding RGLS
Goldman Sachs's RGLS Position: Q2 2025 in Review
Goldman Sachs sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 130,339 shares — an estimated $228K sold.
Goldman Sachs first reported a position in RGLS in Q2 2013 and held it in 25 quarters. The position peaked at $13.6M in Q1 2015. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Goldman Sachs reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Goldman Sachs sold 130,339 Regulus Therapeutics shares in Q2 2025, an estimated $228K.
- Goldman Sachs first reported a position in Regulus Therapeutics in Q2 2013 and held it in 25 quarters.
- Goldman Sachs's Regulus Therapeutics position peaked at $13.6M in Q1 2015.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.